GHRP-2 vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-2
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | GHRP-2 | SS-31 (Elamipretide) |
|---|---|---|
| Mechanism | Binds to the ghrelin receptor (GHS-R) to stimulate GH release from the pituitary. Also has some direct effects on the hypothalamus. Causes less appetite increase than GHRP-6. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often stacked with GHRH peptides for enhanced GH release. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Subcutaneous injection on an empty stomach. Can be used at bedtime to enhance natural GH pulse during sleep. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Moderate hunger increase, water retention, potential prolactin and cortisol elevation (less than GHRP-6), tingling sensations. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |